Ontrak, Inc. OTRK
We take great care to ensure that the data presented and summarized in this overview for Ontrak, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OTRK
Top Purchases
Top Sells
About OTRK
Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to health plans and other third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology-enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Henderson, Nevada.
Insider Transactions at OTRK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2024
|
Michael Edward Sherman |
SELL
Open market or private sale
|
Direct |
173
-100.0%
|
$173
$1.77 P/Share
|
|
Jun 14
2024
|
James J Park Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27
-3.92%
|
$0
$0.25 P/Share
|
|
Jun 14
2024
|
James J Park Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
66
+8.74%
|
-
|
|
Dec 20
2023
|
Terren S Peizer > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
9,027,395
+25.0%
|
$0
$0.6 P/Share
|
|
Nov 14
2023
|
Terren S Peizer > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
18,054,791
+50.0%
|
$0
$0.9 P/Share
|
|
Jun 14
2023
|
Judith Feld Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
222
-27.75%
|
$0
$0.49 P/Share
|
|
Jun 14
2023
|
Judith Feld Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+50.0%
|
-
|
|
Jun 14
2023
|
James J Park Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
269
-6.73%
|
$0
$0.49 P/Share
|
|
Jun 14
2023
|
James J Park Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+16.67%
|
-
|
|
Feb 21
2023
|
Terren S Peizer > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
2,038,133
+14.63%
|
-
|
|
Sep 01
2022
|
Mary Louise Osborne Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
$0
$0.66 P/Share
|
|
Aug 30
2022
|
Brandon H La Verne Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
$0
$0.65 P/Share
|
|
Aug 29
2022
|
Terren S Peizer > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
739,645
+6.98%
|
-
|
|
May 24
2022
|
Arik Hill Chief Information Officer |
BUY
Open market or private purchase
|
Direct |
25,358
+32.92%
|
$25,358
$1.44 P/Share
|
|
May 20
2022
|
Arik Hill Chief Information Officer |
BUY
Open market or private purchase
|
Direct |
26,315
+50.0%
|
$26,315
$1.52 P/Share
|
|
Sep 28
2021
|
Terren S Peizer > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,567
-0.15%
|
$135,670
$10.23 P/Share
|
|
Sep 27
2021
|
Terren S Peizer > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-0.08%
|
$150,000
$10.17 P/Share
|
|
Sep 24
2021
|
Terren S Peizer > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-0.16%
|
$135,000
$9.59 P/Share
|
|
Sep 23
2021
|
Terren S Peizer > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-0.16%
|
$150,000
$10.11 P/Share
|
|
Sep 22
2021
|
Terren S Peizer > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-0.16%
|
$150,000
$10.22 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 9.03M shares |
|---|---|
| Exercise of conversion of derivative security | 66 shares |
| Open market or private sale | 173 shares |
|---|---|
| Payment of exercise price or tax liability | 27 shares |